by TractManager | Jun 16, 2022 | Emerging Technology Report
Pegzilarginase is an investigational recombinant form of the human enzyme arginase 1 (ARG1) proposed for the treatment of pediatric and adult patients with ARG1 deficiency. It is administered by intravenous infusion or subcutaneous injection.If you have a Hayes login,...
by TractManager | Jun 7, 2022 | Health Technology Assessment
Focus of the Report: This Health Technology Assessment focuses on percutaneous pulmonary valve implantation (PPVI) with Edwards Sapien 3 or Sapien XT valves for the treatment of right ventricular outflow tract (RVOT) defects.Technology Description: The goal of PPVI is...
by TractManager | Jun 6, 2022 | Publications
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Siren Socks (Siren Care Inc.) for prediction of diabetic foot ulcers.
by TractManager | Jun 3, 2022 | Health Technology Assessment
Focus of the Report: This Health Technology Assessment (HTA) focuses on the use of the Micra transcatheter pacing system (TPS) (Medtronic Inc.) as a leadless alternative to traditional transvenous pacemakers (TVPMs) for the management of patients with bradycardia or...
by TractManager | Jun 3, 2022 | Emerging Technology Report
Fexapotide triflutate is an investigational injectable apoptotic agent proposed for the treatment of benign prostatic hypertrophy (BPH).If you have a Hayes login, click here to view the full report on the Knowledge Center.
Recent Comments